# Alectinib Pharmacokinetic in Patients With NSCLC

> **NCT05713006** · PHASE1,PHASE2 · RECRUITING · sponsor: **Instituto Nacional de Cancerologia de Mexico** · enrollment: 45 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer Stage IIIB
- ALK Gene Mutation

## Interventions

- **DRUG:** Alectinib Oral Product

## Key facts

- **NCT ID:** NCT05713006
- **Lead sponsor:** Instituto Nacional de Cancerologia de Mexico
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-05-01
- **Primary completion:** 2026-12-01
- **Final completion:** 2027-12-01
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2026-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05713006

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05713006, "Alectinib Pharmacokinetic in Patients With NSCLC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05713006. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*